Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM6B | O15054 | 2/20 | 0.44 |
| ▸ | KDM5C | P41229 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18367650 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL19726578 | 0.94 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL22702107 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL18378724 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL18378757 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL22702062 | 0.84 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL19726579 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL19732305 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL18379297 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL20173261 | 0.77 | ALDH1A1 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316017-B2 | COT modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | SMN1; SMN2 4716/4885NPC1 4279/4885RAB9A 4028/4885 |
| US-10316017-B2 | COT modulators and methods of use thereof | BRDT, THRB, HCCS | SMN1; SMN2 4716/4885NPC1 4279/4885RAB9A 4028/4885 |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | SMN1; SMN2 4716/4885NPC1 4279/4885RAB9A 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.